Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations.
作者信息
Padmanabhan Pranesh, Dixit Narendra M
机构信息
Queensland Brain Institute, University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.
Department of Chemical Engineering, Indian Institute of Science, Bangalore 560012, India;
出版信息
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4524-E4526. doi: 10.1073/pnas.1704531114. Epub 2017 May 16.
Abstract
摘要
相似文献
1
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations.
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4524-E4526. doi: 10.1073/pnas.1704531114. Epub 2017 May 16.
2
Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6852-5. doi: 10.1016/j.bmcl.2011.09.019. Epub 2011 Sep 16.
3
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
Gut. 2015 Mar;64(3):483-94. doi: 10.1136/gutjnl-2013-306155. Epub 2014 May 21.
4
Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
Bioorg Med Chem Lett. 2013 Dec 1;23(23):6467-73. doi: 10.1016/j.bmcl.2013.09.039. Epub 2013 Sep 21.
5
Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.
Gut. 2015 Apr;64(4):690-1. doi: 10.1136/gutjnl-2014-308396. Epub 2014 Oct 6.
6
Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.
Gut. 2015 Mar;64(3):362-4. doi: 10.1136/gutjnl-2014-307452. Epub 2014 Aug 6.
7
A novel small molecule inhibitor of hepatitis C virus entry.
PLoS Pathog. 2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086.
8
Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
J Virol. 2017 Jan 3;91(2). doi: 10.1128/JVI.01914-16. Print 2017 Jan 15.
9
Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.
Clin Liver Dis. 2015 Nov;19(4):605-17, v. doi: 10.1016/j.cld.2015.06.002. Epub 2015 Jul 26.
10
Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors and .
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02354-16. Print 2017 May.
引用本文的文献
1
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
PLoS Comput Biol. 2020 Dec 8;16(12):e1008461. doi: 10.1371/journal.pcbi.1008461. eCollection 2020 Dec.
2
Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.
PLoS Pathog. 2019 Apr 1;15(4):e1007701. doi: 10.1371/journal.ppat.1007701. eCollection 2019 Apr.
3
Building a mechanistic mathematical model of hepatitis C virus entry.
PLoS Comput Biol. 2019 Mar 18;15(3):e1006905. doi: 10.1371/journal.pcbi.1006905. eCollection 2019 Mar.
4
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.
Immunol Rev. 2018 Sep;285(1):55-71. doi: 10.1111/imr.12689.
5
Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.
PLoS Comput Biol. 2018 Jul 12;14(7):e1006335. doi: 10.1371/journal.pcbi.1006335. eCollection 2018 Jul.
6
Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16.
本文引用的文献
1
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1922-1927. doi: 10.1073/pnas.1610197114. Epub 2017 Feb 7.
2
Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Hepatology. 2016 Nov;64(5):1495-1506. doi: 10.1002/hep.28767. Epub 2016 Sep 30.
3
Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.
Hepatol Int. 2016 Sep;10(5):741-8. doi: 10.1007/s12072-016-9724-7. Epub 2016 Apr 5.
4
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.
PLoS One. 2012;7(4):e35351. doi: 10.1371/journal.pone.0035351. Epub 2012 Apr 24.
5
A quantitative basis for antiretroviral therapy for HIV-1 infection.
Nat Med. 2012 Feb 19;18(3):446-51. doi: 10.1038/nm.2649.
6
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
Nat Med. 2011 May;17(5):589-95. doi: 10.1038/nm.2341. Epub 2011 Apr 24.
7
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.
J Hepatol. 2011 Jan;54(1):48-55. doi: 10.1016/j.jhep.2010.06.024. Epub 2010 Aug 21.
8
A novel small molecule inhibitor of hepatitis C virus entry.
PLoS Pathog. 2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086.
9
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
J Virol. 2007 Aug;81(15):8101-11. doi: 10.1128/JVI.00127-07. Epub 2007 May 23.
10
Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.
J Virol. 2006 May;80(10):4940-8. doi: 10.1128/JVI.80.10.4940-4948.2006.
Zotero 插件